Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release 7 Hills Pharma Receives 2m Sbir Grant From Nci To Launch Phase 1 Trials Of Lead Immunostimulant To Augment Immuno Oncology Drugs Covid 19 And Flu Vaccines is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
What the phase 1 trials of the first COVID-19 vaccine really mean
Early morning on May 18, Moderna, a biotechnology company, revealed the preliminary findings for the much anticipated phase I trial of an mRNA COVID ... press release lacking some key details ... Read More
FSD Pharma Announces Debt Settlement
TORONTO, ON / ACCESSWIRE / February 28, 2024 / FSD Pharma ... of $1.17 per Class B Share (the "Debt Settlement"). The Company also announced that its board of directors has approved a grant ... Read More
Press Release Portal
Does your organization or business have an announcement to promote? The Marietta Daily Journal's self-service Press Release Portal can get your organization's announcement the placement it needs. Read More
Wayne County Foundation receives $1.5 million grant from Lilly Endowment's GIFT VIII initiative
The Wayne County Foundation is in the eighth phase of Lilly Endowment Inc.'s "Giving Indiana Funds for Tomorrow" initiative. In a press release ... Foundation receives $1.5 million grant from ... Read More
Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c
In 2023, the safety data collected in a phase Ib multiple ascending dose study showed NX210c to be well-tolerated and without safety concerns. Axoltis Pharma, a French biopharma company, develops ... Read More
Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
FDA Agrees with the Study Design of Randomizing Up To 60 Participants with Nodular Type of Basal Cell Carcinoma Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Medicus Pharma Ltd. (TSXV ... was ... Read More
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future ... Read More
Arbor Circle receives $1.2M grant for work with LGBTQ+ youth
The organization received the $1.2 million grant ... in the release. “How might we ensure all LGBTQ+ youth in West Michigan live in a safe, secure community?” Help is available 24/7 for ... Read More
Redwood Pharma AB receives observation status
Today, on March 21, 2024, Redwood Pharma AB (the “Company”) disclosed a press release with information on the Company’s financial situation. The rules of Nasdaq First North Growth ... Read More
Exeliom Biosciences announces three phase II clinical trials in immuno-oncology with lead candidate combined with immune checkpoint inhibitors
Phase II clinical trials will investigate efficacy ... company developing new therapies in immuno-oncology and immuno-inflammation, today announces the launch of three phase II clinical studies of its ... Read More
press release
but the time-proven value of a press release crafted specifically with the current marketplace in mind is still very much on trend and in fashion. You know the saying "Any press is good press"? Read More
Submit a Press Release
Your submission must include your full name, organization name, e-mail address and a valid phone number where you can be reached. We also invite you to attach a digital photograph for publication ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus